ArticleVirchows Archiv : an international journal of pathology2004
Pattern of p63 expression in squamous cell carcinoma of the oral cavity.
Article in Virchows Archiv : an international journal of pathology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 58 citations in OpenAlex.
- TIP60 enhances cisplatin resistance via regulating ΔNp63α acetylation in SCC.Cell death & disease · 2024Article
- The dual role of p63 in cancer.Frontiers in oncology · 2023Review
- Proteomic analysis reveals key differences between squamous cell carcinomas and adenocarcinomas across multiple tissues.Nature communications · 2022Article
- Emerging roles of alternative RNA splicing in oral squamous cell carcinoma.Frontiers in oncology · 2022Review
- Expression of p53, p63, podoplanin and Ki-67 in recurring versus non-recurring oral leukoplakia.Scientific reports · 2021Article
- p63 expression in human tumors and normal tissues: a tissue microarray study on 10,200 tumors.Biomarker research · 2021Article
- Flavopereirine Suppresses the Progression of Human Oral Cancer by Inhibiting the JAK-STAT Signaling Pathway via Targeting LASP1.Drug design, development and therapy · 2021Article
- Human Papilloma Virus Increases ΔNp63α Expression in Head and Neck Squamous Cell Carcinoma.Frontiers in cellular and infection microbiology · 2020Article
- Immunohistochemical evaluation of p63 and cyclin D1 in oral squamous cell carcinoma and leukoplakia.Journal of the Korean Association of Oral and Maxillofacial Surgeons · 2017Article
- CD147 and Ki-67 overexpression confers poor prognosis in squamous cell carcinoma of oral tongue: a tissue microarray study.Oral surgery, oral medicine, oral pathology and oral radiology · 2015Article
- p63 short isoforms are found in invasive carcinomas only and not in benign breast conditions.Virchows Archiv : an international journal of pathology · 2010Article
- p63 Immunoexpression in lip carcinogenesis.Journal of molecular histology · 2009Article
- Expression pattern of p63 in oral epithelial lesions and submucous fibrosis associated with betel-quid chewing in Sri Lanka.Medical molecular morphology · 2007Article
- Rapid development of salivary gland carcinomas upon conditional expression of K-ras driven by the cytokeratin 5 promoter.The American journal of pathology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
P63 is a recently discovered gene harbouring different isoforms by alternate splicing. The two main isoforms, TAp63 and Delta Np63, have opposite functions, being responsible for cell-cycle arrest and cell proliferation, respectively. In addition, new isoforms have been described with the same sequence as TAp63 and Delta Np63, but lacking exon 4 (Delta 4Tap63 and Delta Np73L). P63 as detected using immunohistochemistry is present in squamous cell carcinomas. To better define the role of p63 in squamous cell carcinomas of the oral cavity (OSCC), 39 patients were investigated using immunohistochemical analysis with a monoclonal antibody recognising all p63 isoforms and an anti-Ki67 antibody. Reverse-transcription polymerase chain reaction (PCR) and nested PCR were also performed using isoform-specific primers to evaluate the p63 mRNA expression pattern. Using immunohistochemistry, p63 was always present in OSCC, and its distribution was similar to that of Ki67. The percentage of positive cells increased from normal to neoplastic mucosa, but there was no relationship between the number of p63 positive cells and prognosis. P63 mRNA was found in all patients. The truncated isoforms Delta 4TAp63 and Delta Np73L were more frequently expressed in patients presenting with metastases. Delta Np73L was found in 66.6% of tumours with lymph-node metastases, but in only 33.3% of those devoid of lymph-node metastases at presentation. An impaired expression of the p63 isoforms might favour cell proliferation and indirectly enhance the metastasising capacity of OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.